Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylethanolamine binding protein 1 pseudogene 2 (PEBP1P2)
- Target
- PEBP1P2
- Molecular classification
- Other (Pseudogene-derived long non-coding RNA), Long non-coding RNA (lncRNA)
01
Overview
Phosphatidylethanolamine binding protein 1 pseudogene 2 (PEBP1P2) is a non-coding RNA transcribed from a pseudogene homologous to PEBP1. Distinguished from classical protein-coding targets, PEBP1P2 functions as a regulatory lncRNA that suppresses cancer metastasis and abnormal vascular cell proliferation/migration. Low expression of PEBP1P2 is associated with poor prognosis in clear cell renal cell carcinoma, while high expression exerts protective effects in cardiovascular disease models. Mechanistically, PEBP1P2 stabilizes specific mRNAs and acts as a sponge for microRNAs, positioning it as a promising molecular target for future therapeutics and biomarker studies[1][2][12].
- Other names
- lncRNA5long non-coding RNA PEBP1P2
02
Mechanism of action
Not applicable for direct drug action; however, overexpression (genetic upregulation) of PEBP1P2 decreases cell proliferation, migration, and metastasis by stabilizing target mRNAs and sponging microRNAs
03
Biological functions
Regulates cell proliferation and migration in vascular smooth muscle cells (VSMCs)Inhibits metastasis formation in clear cell renal cell carcinoma (ccRCC)Stabilizes mRNA (PEBP1 mRNA via RNA-protein interactions)Post-transcriptionally regulates gene expression (acts as a sponge for microRNAs, e.g. miR-296, miR-616, miR-3194)Regulates VSMC phenotypic switching
04
Disease associations
Cancer: Suppresses metastasis and correlates with prognosis in clear cell renal cell carcinoma (ccRCC)Cardiovascular disease: Inhibits proliferation and phenotypic switching of vascular smooth muscle cells, possibly valuable in atherosclerosis and restenosisOther: Potential regulatory role in pathological arterial remodeling
05
Safety considerations
None reported; as a non-coding RNA, safety concerns would relate to delivery or off-target effects in future therapeutic applications
06
Interacting drugs
None known; no drugs reported to interact directly with PEBP1P2
07
Biomarkers
PEBP1P2 expression in tissue/serum may serve as a biomarker for prognosis in ccRCC and coronary heart disease; decreased PEBP1P2 correlates with disease severity
Beyond the preview
Go deeper on Phosphatidylethanolamine binding protein 1 pseudogene 2 (PEBP1P2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phosphatidylethanolamine binding protein 1 pseudogene 2 (PEBP1P2).